Victrex (LON:VCT) Announces Quarterly Earnings Results

Victrex (LON:VCT) announced its quarterly earnings results on Monday. The company reported GBX 17.20 EPS for the quarter, Digital Look Earnings reports. The business had revenue of £147.10 million during the quarter. Victrex had a return on equity of 6.40% and a net margin of 9.50%.

Here are the key takeaways from Victrex’s conference call:

• Victrex’s H1 revenue rose 1% to GBP 147.1 million, helped by a strong Q2 and 6% volume growth, but pricing and mix offset some of the benefit.
• Profitability weakened, with underlying PBT down 18% to GBP 19 million and gross margin falling to 41.7% from 44.1% due to price pressure, mix, currency, and softer medical sales.
• Cash generation remained solid, with free cash flow of GBP 22 million, cash conversion of 109%, and net debt at a manageable 0.65x EBITDA.
• The company recorded a GBP 60.6 million non-cash impairment on its China manufacturing plant after concluding one production step is limiting capacity versus the original 1,500-ton nameplate. Management emphasized this is an operational issue, not a demand issue, and China demand remains strong.
• Management is taking aggressive restructuring actions, including a 10% global headcount reduction, a new decentralized operating model, and portfolio simplification, with a September capital markets day planned to detail the strategy and medium-term profit improvement plan.

Victrex Stock Down 2.6%

VCT opened at GBX 568.01 on Tuesday. The business has a 50 day moving average price of GBX 607.92 and a 200 day moving average price of GBX 644.06. Victrex has a twelve month low of GBX 515 and a twelve month high of GBX 865. The company has a debt-to-equity ratio of 11.30, a quick ratio of 1.99 and a current ratio of 3.01. The firm has a market cap of £494.87 million, a P/E ratio of 17.86, a price-to-earnings-growth ratio of 1.92 and a beta of 0.75.

Key Stories Impacting Victrex

Here are the key news stories impacting Victrex this week:

• Negative Sentiment: Victrex reported lower first-half profit, indicating softer operating performance and reduced earnings momentum. Victrex reports lower first-half profit
• Negative Sentiment: The company said it is accelerating its restructuring programme and will cut about 10% of jobs after issues at its China plant hurt profits, suggesting additional costs and operational headwinds. Victrex to axe 10% of jobs after China plant trouble hit profits
• Negative Sentiment: Victrex also said profit declined as the restructuring programme accelerated, reinforcing concerns that near-term earnings may remain under pressure. Victrex (VCT) Sees Profit Decline as Restructuring Programme Accelerates
• Neutral Sentiment: UBS Group reaffirmed its sell rating on Victrex and kept a GBX 575 price target, which may add to cautious sentiment but does not introduce new company-specific fundamentals. Victrex’s (VCT) Sell Rating Reaffirmed at UBS Group
• Neutral Sentiment: Victrex also released quarterly earnings showing EPS of GBX 17.20 on revenue of £147.1 million, which provides updated financial context but was not as clearly supportive as the restructuring headlines. Victrex earnings report

Analyst Ratings Changes

Several equities research analysts recently commented on VCT shares. JPMorgan Chase & Co. lowered their price target on Victrex from GBX 725 to GBX 625 and set a “buy” rating for the company in a research note on Wednesday, March 18th. UBS Group reissued a “sell” rating and issued a GBX 575 price target on shares of Victrex in a research note on Monday. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a GBX 725 price target on shares of Victrex in a research note on Monday, April 13th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of GBX 720.83.

Victrex Company Profile

Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.